Operating Segments (Tables)

3 Months Ended

12 Months Ended

Mar. 31, 2018

Dec. 31, 2017

Operating Segments [Abstract]

Summary of operating segments

	Three Months Ended March 31,
	2018			2017
Revenues
Vaccines/BioDefense	$	809,256		$	1,330,884
BioTherapeutics		310,517			-
Total	$	1,119,773		$	1,330,884
Income/(Loss) from Operations
Vaccines/BioDefense	$	(86,205	)	$	136,600
BioTherapeutics		(1,521,348	)		(1,027,555	)
Corporate		(786,548	)		(847,235	)
Total	$	(2,394,101	)	$	(1,738,190	)
Amortization and Depreciation Expense
Vaccines/BioDefense	$	4,480		$	9,769
BioTherapeutics		5,384			9,567
Corporate		1,350			1,714
Total	$	11,214		$	21,050
Interest Income, Net
Corporate	$	16,895		$	4,753
Share-Based Compensation
Vaccines/BioDefense	$	15,668		$	17,998
BioTherapeutics		28,318			49,770
Corporate		63,984			78,859
Total	$	107,970		$	146,627

	As of March 31, 2018		As of December 31, 2017
Identifiable Assets
Vaccines/BioDefense	$	768,868	$	906,416
BioTherapeutics		146,404		116,344
Corporate		6,563,527		8,526,891
Total	$	7,478,799	$	9,549,651

	For the Years Ended December 31,
	2017			2016
Revenues
Vaccines/BioDefense	$	4,749,294		$	10,448,794
BioTherapeutics		683,178			-
Total	$	5,432,472		$	10,448,794
Income (Loss) from Operations
Vaccines/BioDefense	$	232,166		$	1,563,884
BioTherapeutics		(4,181,811	)		(3,399,933	)
Corporate		(3,644,154	)		(3,873,533	)
Total	$	(7,593,799	)	$	(5,709,582	)
Amortization and Depreciation Expense
Vaccines/BioDefense	$	33,183		$	40,186
BioTherapeutics		30,614			41,395
Corporate		4,766			8,347
Total	$	68,563		$	89,928
Other Income, Net
Corporate	$	29,906		$	1,934,056
Share-Based Compensation
Vaccines/BioDefense	$	76,625		$	99,410
BioTherapeutics		137,319			131,163
Corporate		275,843			344,404
Total	$	489,787		$	574,977

		As of December 31,
		2017		2016
Identifiable Assets
Vaccines/BioDefense	$	906,416	$	1,297,986
BioTherapeutics		116,344		49,422
Corporate		8,526,891		8,919,698
Total	$	9,549,651	$	10,267,105